Self-Selection Doubts Are No Friend To Alli As Xenical Heads For Switch Panel
This article was originally published in The Tan Sheet
Executive Summary
FDA has cited a number of unresolved consumer safety concerns in GlaxoSmithKline's Rx-to-OTC switch application for weight-loss drug Alli (Xenical/orlistat 60 mg) stemming from self-selection issues observed in the drug's actual use study
You may also be interested in...
Alli Makes Passing Grade On Safety; Advisory Committee Debates Benefit
Orlistat's benefit in an over-the-countersetting is questionable, but the safety of the weight-loss drug creates a risk/benefit ratio in favor of nonprescription use, an FDA advisory panel expressed in an 11-3 vote Jan. 23
Future Alli Actual Use, Label Comprehension Commitments Likely
GlaxoSmithKline could be asked to conduct more actual use research to support the possible transition of the weight loss drug Xenical (orlistat) from prescription to over-the-counter sale
Alli Makes Passing Grade On Safety; Advisory Committee Debates Benefit
Orlistat's benefit in an over-the-countersetting is questionable, but the safety of the weight-loss drug creates a risk/benefit ratio in favor of nonprescription use, an FDA advisory panel expressed in an 11-3 vote Jan. 23